1,572 results match your criteria anti-d igg

Hyporegenerative anemia in anti-M-associated hemolytic disease of the fetus.

Transfusion 2021 Jun 3;61(6):1908-1915. Epub 2021 May 3.

Department of Obstetrics, the Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.

Background: The anti-M antibody can lead to hemolytic disease of the fetus and newborn (HDFN) and adverse fetal outcomes, especially in the Asian population. However, fetal erythropoiesis resulting from M alloimmunization needs further investigation.

Study Design And Methods: We analyzed erythropoiesis in eight fetuses with M alloimmunization and compared them with the fetuses affected by anti-D. Read More

View Article and Full-Text PDF

Red-cell alloimmunization profile in multi transfused patients: Findings and insights of a blood transfusion service.

Transfus Clin Biol 2021 Apr 24. Epub 2021 Apr 24.

Hematology and Transfusion Medicine Center -University of Campinas/Hemocentro-Unicamp, Campinas, São Paulo, Brazil; Universidade São Francisco, Bragança Paulista, São Paulo, Brazil.

Objectives: Blood transfusion is a key intervention for decreasing morbidity and mortality in many cases and, besides its importance, potentially fatal consequences of incompatible transfusion are a great risk to patients. This study evaluated the incidence and specificity of erythrocyte alloantibodies in multi-transfused patients enrolled at an important Regional Blood Center.

Materials/methods: This was a single-center retrospective cohort study that eveluated patients enrolled at a Regional Blood Center in a period of four years. Read More

View Article and Full-Text PDF

Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.

Transfusion 2021 06 22;61(6):1705-1709. Epub 2021 Mar 22.

Grifols Bioscience Industrial Group, Research Triangle Park, North Carolina, USA.

Background: In late 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus emerged in China and quickly spread into a worldwide pandemic. Prior to the development of specific drug therapies or a vaccine, more immediately available treatments were sought including convalescent plasma. A potential improvement from convalescent plasma could be the preparation of anti-SARS-CoV-2 hyperimmune globulin (hIVIG). Read More

View Article and Full-Text PDF

Screening of RHD fetal genotype in RhD negative women.

Ceska Gynekol 2020 ;85(3):156-163

Objective: In the Czech Republic in all women within a first trimester screening a laboratory testing for RhD blood group from the peripheral blood should be performed. The aim of the screening is to diagnose RhD negative pregnant women, who may be at risk of developing RhD alloimmunization if the fetus is RhD positive. Currently, the prevention of RhD alloimmunization is carried out regardless of the knowledge of RHD fetal status. Read More

View Article and Full-Text PDF
February 2021

Clinical Characteristics and Outcomes of Pediatric Patients With Immune Thrombocytopenic Purpura in King Abdulaziz Medical City and King Abdullah Specialist Children's Hospital: A 10-Year Study.

Cureus 2020 Nov 6;12(11):e11366. Epub 2020 Nov 6.

Medicine, King Saud Bin Abdulaziz University for Health Sciences College of Medicine, Riyadh, SAU.

Background Immune thrombocytopenic purpura (ITP) can be defined as "an immune-mediated acquired disease characterized by a transient or persistent decrease in the platelet count". Medical treatment is usually not needed but, in some cases, intravenous immunoglobulin G (IVIG), corticosteroids, and anti-D immunoglobulins are used. Splenectomy can be an option for chronic cases with no response to pharmacological treatments. Read More

View Article and Full-Text PDF
November 2020

Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia.

Expert Rev Hematol 2020 12 30;13(12):1319-1332. Epub 2020 Nov 30.

Division of Hematology, Massachusetts General Hospital, Harvard Medical School , Boston, MA, USA.

: Three distinct phases are recognized in immune thrombocytopenia (ITP): newly diagnosed (≤3 months after diagnosis), persistent (>3-12 months after diagnosis), and chronic (>12 months). Several international guidelines/expert recommendations have been released in the past 2 years regarding the treatment of newly diagnosed/persistent ITP. : Across the guidelines/expert recommendations, thrombopoietin receptor agonists (TPO-RAs), including romiplostim (the focus of this review), are recommended in newly diagnosed or persistent ITP for patients who fail to respond to corticosteroids or intravenous immunoglobulin (or where these are contraindicated). Read More

View Article and Full-Text PDF
December 2020

Seroepidemiological Study of Canine and Human Dirofilariasis in the Endemic Region of Northern Serbia.

Front Vet Sci 2020 29;7:571. Epub 2020 Sep 29.

Group of Animal and Human Dirofilariasis, Faculty of Pharmacy, Campus Miguel Unamuno, University of Salamanca, Salamanca, Spain.

Dirofilariasis is a vector-borne zoonotic disease caused mainly by and that affect dogs and humans all over the world. Serbia is considered an endemic country to both forms of dirofilariasis, although most of the population is concentrated in the north of the country. The aims of this study were to show the prevalence of and in dogs and the seroprevalence in humans compared to previous studies in Northern Serbia. Read More

View Article and Full-Text PDF
September 2020

FIGO/ICM guidelines for preventing Rhesus disease: A call to action.

Int J Gynaecol Obstet 2021 Feb 9;152(2):144-147. Epub 2021 Jan 9.

Worldwide Initiative for Rh Disease Eradication, New York, NY, USA.

The introduction of anti-Rh(D) immunoglobulin more than 50 years ago has resulted in only a 50% decrease in Rhesus disease globally owing to a low uptake of this prophylactic approach. The International Federation of Gynecology and Obstetrics, International Confederation of Midwives, and Worldwide Initiative for Rhesus Disease Eradication have reviewed current evidence regarding the utility of anti-Rh(D) immunoglobulin. Taking into account the effectiveness anti-Rh(D), the new guidelines propose adjusting the dose for different indications and prioritizing its administration by indication. Read More

View Article and Full-Text PDF
February 2021

Aggregates in blood filter chambers used from the plasma donations of anti-D donors: evaluation for monoclonal antibody discovery using phage display.

Blood Transfus 2021 Jan 9;19(1):64-72. Epub 2020 Oct 9.

Research and Development, Australian Red Cross Lifeblood, Brisbane, Australia.

Background: RhD-immunoglobulin (RhIg) prevents anti-D alloimmunisation in D-negative pregnant women when the fetus is D-positive, reducing the incidence of haemolytic disease of the fetus and newborn. Manufacturing RhIg is reliant on the limited supply of plasma donations with anti-D antibodies. Monoclonal antibody (mAb) development platforms such as phage display, require blood samples to be collected from anti-D donors, which may be a complicated process. Read More

View Article and Full-Text PDF
January 2021

Fetal and Neonatal Alloimmune Thrombocytopenia-New Prospects for Fetal Risk Assessment of HPA-1a-Negative Pregnant Women.

Transfus Med Rev 2020 10 16;34(4):270-276. Epub 2020 Sep 16.

Department of Clinical Immunology and Transfusion Medicine, University and Regional Laboratories, Region Skåne, Lund, Sweden.

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a rare and potentially serious bleeding condition in the fetus/newborn. FNAIT is usually considered as the platelet counterpart of hemolytic disease of the fetus and newborn. In FNAIT, maternal alloantibodies against paternally inherited platelet antigens traverse the placenta and cause thrombocytopenia in the fetus/newborn. Read More

View Article and Full-Text PDF
October 2020

Update on Transplacental Transfer of IgG Subclasses: Impact of Maternal and Fetal Factors.

Front Immunol 2020 11;11:1920. Epub 2020 Sep 11.

Department of Metabolism, Digestion and Reproduction, Institute of Reproductive and Developmental Biology, Imperial College, London, United Kingdom.

Transplacental antibody transfer from mother to fetus provides protection from infection in the first weeks of life, and the four different subclasses of IgG (IgG1, IgG2, IgG3, and IgG4) have diverse roles in protection against infection. In this study, we evaluated concentrations and transplacental transfer ratios of the IgG subclasses in a healthy UK-based cohort of mother-cord pairs, and investigated associations with maternal, obstetric, and fetal factors. In agreement with previous studies, we found a strong association between maternal and cord IgG for all subclasses. Read More

View Article and Full-Text PDF

Elimination of pretransfusion RhD typing at Mackay Memorial Hospital, Taiwan-30-year experience (1988-2017).

Marie Lin

Vox Sang 2021 Feb 20;116(2):234-238. Epub 2020 Sep 20.

Transfusion Medicine Laboratory, Mackay Memorial Hospital, Taipei, Taiwan.

Background: The frequency of the RhD negative (D-) phenotype among the population of Taiwan is only 0·34% and so anti-D is a relatively rare antibody. Routine pretransfusion D typing of patients at Mackay Memorial Hospital (MMH) was discontinued in 1988, and this report is a look back and retrospective evaluation over 30-years (1988-2017).

Study Design And Methods: The incidence of anti-D among patients at MMH during the periods 1984-1988 (when D typing was performed) and 1988-2017 (when D typing was not performed) was reviewed. Read More

View Article and Full-Text PDF
February 2021

Medical therapy to attenuate fetal anaemia in severe maternal red cell alloimmunisation.

Br J Haematol 2021 02 14;192(3):425-432. Epub 2020 Aug 14.

West Midlands Fetal Medicine Centre, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.

Haemolytic disease of the fetus and newborn (HDFN) remains an important cause of fetal mortality with potential neonatal and longer-term morbidity. HDFN is caused by maternal red cell alloimmunisation, with IgG antibodies crossing the placenta to destroy fetal erythroid cells expressing the involved antigen. Intrauterine fetal blood transfusion is the therapy of choice for severe fetal anaemia. Read More

View Article and Full-Text PDF
February 2021

Hemolytic disease of the fetus and newborn due to Rh(D) incompatibility: A preventable disease that still produces significant morbidity and mortality in children.

PLoS One 2020 20;15(7):e0235807. Epub 2020 Jul 20.

Department of Pathology and Cell Biology, Columbia University, New York, NY, United States of America.

In the mid-20th century, Hemolytic Disease of the Fetus and Newborn, caused by maternal alloimmunization to the Rh(D) blood group antigen expressed by fetal red blood cells (i.e., "Rh disease"), was a major cause of fetal and neonatal morbidity and mortality. Read More

View Article and Full-Text PDF
September 2020

Successful treatment of refractory secondary immune thrombocytopenia (antiphospholipid antibody syndrome-associated) with the combination of rituximab and romiplostim at the cost of severe bone pain: A case report and review of literature.

J Oncol Pharm Pract 2021 Jan 1;27(1):253-257. Epub 2020 Jul 1.

Department of Internal Medicine, Istanbul University-Cerrahpasa Faculty of Medicine, Istanbul, Turkey.

Introduction: Immune thrombocytopenia is an autoimmune disorder associated with increased thrombocyte destruction and impaired production in the bone marrow. Proposed mechanisms include an antibody or autoreactive T-cell-associated autoimmunity and thrombopoietin deficiency among others. Clinical manifestations are predominantly mucocutaneous hemorrhages including petechiae, purpura, mucosal bleeding in the urinary or the gastrointestinal tracts, menorrhagia, and epistaxis. Read More

View Article and Full-Text PDF
January 2021

Anti-D selection for D assignment among pregnant women and blood donors: impact of the Crawford antigen.

Transfusion 2020 07 29;60(7):1378-1380. Epub 2020 May 29.

Diagnostic Laboratories, Versiti, Wisconsin, USA.

View Article and Full-Text PDF

RHD genotyping is recommended for all patients with serological weak-D phenotypes in Asian populations - Cases with coexistence of weak-D and Asia type DEL alleles results in complete expression of D-antigen.

Transfus Apher Sci 2020 Aug 11;59(4):102807. Epub 2020 May 11.

Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, South Korea. Electronic address:

Weak D types 1, 2, 3 and Asia type DEL (RHD 1227 G > A) can be treated as D-positive for purposes of Rho(D) immune globulin (RhIG) administration or selection of blood components for transfusion. To confirm these D variants, RHD genotyping can be used as a complementary to serologic tests. While ruling out weak D types 1,2,3 is useful in Caucasian populations, these are extremely rare in the Asian population, while Asia type DEL is relatively common. Read More

View Article and Full-Text PDF

Inhibition of platelet phagocytosis as an in vitro predictor for therapeutic potential of RBC antibodies in murine ITP.

Blood 2020 06;135(26):2420-2424

Keenan Research Centre for Biomedical Science of St. Michael's Hospital, Unity Health Toronto, Toronto, ON, Canada.

Polyclonal anti-D is a first-line therapy for immune thrombocytopenia (ITP). Monoclonal antibodies are desirable alternatives, but none have yet proven successful despite their ability to opsonize erythrocytes (or red blood cells, RBCs) and cause anemia. Here, we examined 12 murine erythrocyte-specific antibodies of different specificity and subtypes and found that 8 of these antibodies could induce anemia in antigen-positive mice. Read More

View Article and Full-Text PDF

Frequency and clinical significance of red cell antibodies in pregnancy - A prospective study from India.

Indian J Pathol Microbiol 2020 Apr-Jun;63(2):241-246

Department of Immunohematology and Blood Transfusion, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, India.

Background: For appropriate management of hemolytic disease of the fetus and newborn (HDFN), it is important to detect irregular red cell antibody in the antenatal period. Though it is a simple one-step method, it is not part of routine antenatal screening in many developing countries. To reiterate the importance of antenatal antibody screening, we have assessed the frequency and clinical significance of irregular red cell antibodies in our patient population. Read More

View Article and Full-Text PDF
January 2021

Vanadium: Risks and possible benefits in the light of a comprehensive overview of its pharmacotoxicological mechanisms and multi-applications with a summary of further research trends.

J Trace Elem Med Biol 2020 Sep 12;61:126508. Epub 2020 Apr 12.

Military Clinical Hospital with the Outpatient Clinic in Lublin, Poland.

Background: Vanadium (V) is an element with a wide range of effects on the mammalian organism. The ability of this metal to form organometallic compounds has contributed to the increase in the number of studies on the multidirectional biological activity of its various organic complexes in view of their application in medicine.

Objective: This review aims at summarizing the current state of knowledge of the pharmacological potential of V and the mechanisms underlying its anti-viral, anti-bacterial, anti-parasitic, anti-fungal, anti-cancer, anti-diabetic, anti-hypercholesterolemic, cardioprotective, and neuroprotective activity as well as the mechanisms of appetite regulation related to the possibility of using this element in the treatment of obesity. Read More

View Article and Full-Text PDF
September 2020

External quality assessment of noninvasive fetal RHD genotyping.

Vox Sang 2020 Jul 12;115(5):466-471. Epub 2020 Mar 12.

Nordic Reference Laboratory for Genomic Blood Group Typing, Department of Clinical Immunology and Transfusion Medicine, Office of Medical Services, Lund, Sweden.

Background And Objectives: Fetal RHD genotyping of cell-free maternal plasma DNA from RhD negative pregnant women can be used to guide targeted antenatal and postnatal anti-D prophylaxis for the prevention of RhD immunization. To assure the quality of clinical testing, we conducted an external quality assessment workshop with the participation of 31 laboratories.

Materials And Methods: Aliquots of pooled maternal plasma from gestational week 25 were sent to each laboratory. Read More

View Article and Full-Text PDF

Clinical value of different anti-D immunoglobulin strategies for preventing Rh hemolytic disease of the fetus and newborn: A network meta-analysis.

PLoS One 2020 12;15(3):e0230073. Epub 2020 Mar 12.

Department of Obstetrics and Gynecology, the First People's Hospital of Neijiang, Neijiang, Sichuan Province, P. R. China.

Background: Several anti-D immunoglobulin strategies exist for preventing Rh hemolytic disease of the fetus and newborn. This study systematically assessed the clinical value of those therapeutic strategies.

Methods: The Web of Science, PubMed, EMBASE, China National Knowledge Infrastructure (CNKI) and Wanfang databases were searched for eligible studies that evaluated the value of different anti-D immunoglobulin strategies in preventing maternal anti-D antibody sensitization. Read More

View Article and Full-Text PDF

Do red cell alloantibodies continue to challenge breast fed babies?

Transfus Med 2020 Aug 21;30(4):281-286. Epub 2020 Feb 21.

Department of Transfusion Medicine and Immunohaematology, Christian Medical College, Vellore, India.

Background: Newborns have limited specific immune capability at birth, owing to delayed and constrained development of adaptive immunity. To supplement this period the mother passively transfers antibodies to the child either transplacentally or through breast milk. When maternal alloimmunisation occurs through foreign or fetal red cell surface antigens, stimulating the production of immunoglobulin G (IgG) antibodies, these IgG antibodies can cross the placenta and cause haemolytic disease of the fetus and the newborn. Read More

View Article and Full-Text PDF

Mitigation strategies for anti-D alloimmunization by platelet transfusion in haematopoietic stem cell transplant patients: a survey of NCCN centres.

Vox Sang 2020 May 20;115(4):334-338. Epub 2020 Feb 20.

Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.

Background And Objectives: D-negative patients are at risk of developing an alloantibody to D (anti-D) if exposed to D during transfusion. The presence of anti-D can lead to haemolytic transfusion reactions and haemolytic disease of the newborn. Anti-D alloimmunization can also complicate allogeneic haematopoietic stem cell transplantation (HSCT) with haemolysis and increased transfusion requirements. Read More

View Article and Full-Text PDF

Medical care or clinical research on humans? Contaminated anti-D immunoglobulin in the GDR and its consequences.

Z Gastroenterol 2020 Feb 12;58(2):127-132. Epub 2020 Feb 12.

Institute of the History, Philosophy and Ethics of Medicine, Universität Ulm, Germany.

Background:  In 1978 and 1979, contaminated anti-D immunoglobulin was used in the German Democratic Republic (GDR). As a result, several thousand women were, in the end, infected with hepatitis C. These women received medical attention, part of which was research on hepatitis C. Read More

View Article and Full-Text PDF
February 2020

Rhesus D factor (RhD) negative women's experiences with pregnancy: An interpretive description.

Women Birth 2020 Nov 5;33(6):e511-e518. Epub 2020 Feb 5.

School of Nursing, University of Northern British Columbia, 3333 University Way, Prince George, British Columbia, V2N 4Z9, Canada.

Background: The development of rh immune globulin (RhIG) for the prevention of Rhesus D (RhD) alloimmunization has significantly decreased the incidence of RhD alloimmunization. Despite long-standing prevention, the experiences of RhD negative women with pregnancy is absent in the literature.

Aim: The purpose of this study was to explore the experiences of RhD negative women with pregnancy. Read More

View Article and Full-Text PDF
November 2020

Targeted antenatal anti-D prophylaxis for RhD-negative pregnant women: a systematic review.

BMC Pregnancy Childbirth 2020 Feb 7;20(1):83. Epub 2020 Feb 7.

Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany.

Background: All non-sensitized Rhesus D (RhD)-negative pregnant women in Germany receive antenatal anti-D prophylaxis without knowledge of fetal RhD status. Non-invasive prenatal testing (NIPT) of cell-free fetal DNA in maternal plasma could avoid unnecessary anti-D administration. In this paper, we systematically reviewed the evidence on the benefit of NIPT for fetal RhD status in RhD-negative pregnant women. Read More

View Article and Full-Text PDF
February 2020

Anti-D monoclonal antibodies from 23 human and rodent cell lines display diverse IgG Fc-glycosylation profiles that determine their clinical efficacy.

Sci Rep 2020 01 30;10(1):1464. Epub 2020 Jan 30.

Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands.

Anti-D immunoglobulin (Anti-D Ig) prophylaxis prevents haemolytic disease of the fetus and newborn. Monoclonal IgG anti-Ds (mAb-Ds) would enable unlimited supplies but have differed in efficacy in FcγRIIIa-mediated ADCC assays and clinical trials. Structural variations of the oligosaccharide chains of mAb-Ds are hypothesised to be responsible. Read More

View Article and Full-Text PDF
January 2020